HSP90AB1 and hepatocellular carcinoma: Zhou and co-workers reported that HSP90 CTD domain inhibitor novobiocin resulted in proteasomal degradation of Bclaf, reduced c-Myc mRNA and inhibited hepatocellular carcinoma growth, suggesting that targeting HSP90 CTD domain may be a promising strategy for tumors with Bclaf upregulation (51).